X
Roche claims EU okay for Herceptin/Perjeta combination Phesgo
https://pharmaphorum.com/news/roches-claims-eu-okay-for-herceptin-perjeta-combination-phesgo/
HER2-positive breast cancer
Roche’s Perjeta combo approved in Europe for early breast cancer
The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.